Clinical trials for genomic

[Elodie_Espesset]

Tazemetostat is a EZH2 inhibitor in trial. You can find some information about it here:

Tazemetostat

Epizyme just announced that it intends to initiate a phase 1 trial of EZH2 inhibitor tazemetostat for synovial sarcoma: http://www.epizyme.com/wp-content/uploads/2015/08/EPZM_News_2015_8_6_General_Releases.pdf It looks like the clinical trial will be in Europe and Australia: https://clinicaltrials.gov/ct2/show/NCT01897571 Apparently EZH2 high expression is associated with poor prognosis in synovial sarcoma: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494513/ The trial may be particularly intere…

One of our members, Kaiowas reported his experience here (negative):

Epizyme EZH2 Inhibitor — EPZ-6438, Tazemetostat

Hi - we are looking into going on the trial at Memorial Sloan on the Epizyme EZH2 inhibitor EPZ-6438, Tazemetostat. Has anyone tried this? Can you please share your experience? Thank you. Trish

He may not have a mutation in SMARCB1 though. Usually SMARCB1 function is disrupted by the SYT-SSX translocation in synovial sarcoma. Your case sounds different.
The only hedgehog inhibitor mentioned on this site is GDC-0449 here:

Seeking advice re: clinical trials

After having an initially impressive response to Yondelis (appx. 80% shrinkage in lung and pleural tumors! WOW!), my wife's latest CT shows that her tumors are growing again. She's being treated at Memorial Sloan-Kettering in NYC, and has essentially been offered two choices: 1. Phase II trial of oral gamma-secretase Notch inhibitor RO4929097 alone or with oral Hedgehog antagonist GDC-0449 (see http://clinicaltrials.gov/ct2/show/NCT01154452). 2. Gemzar + Taxotere. As far as I can tell, nei…

The trial was completed and some results are posted here showing the company chose to discontinue the trial:
https://clinicaltrials.gov/ct2/show/results/NCT01154452?sect=X01256#all
So far, only a few CDK4/6 inhibitors trials have been dedicated to sarcoma, usually targeting liposarcoma and nothing for synovial sarcoma specifically. There may be trials for solid tumor. A few CDK4/6 inhibitors are palbociclib, abemaciclib, ribociclib.
Votrient is a FGFR inhibitor, approved for sarcoma treatment.
Ellen’s son tried an aurora kinase inhibitor years ago:

Adaptive Immunotherapy NY-NSE0-1 and ALISERTIB (MLN8237) and COILS

I haven’t written in a while as James has been on a sarcoma rollercoaster. First, we went to Bethesda, MD for the NY-ESO-1 immunotherapy study after he was weaned from chemo for 3 weeks. He had extensive lab work and studies done, met with several research nurses, a social worker, a fellow and several doctors. We were told that he would come back in a week (if he met the criteria) and his T cells would be cloned and grown. This process would take 4 more weeks (in which you had to be chemo-free …

It didn’t work for him as he passed away shortly after. It looks like the trial was suspended:
https://clinicaltrials.gov/ct2/show/NCT01653028